HomeGLAND › Filing
🔔 Get instant alerts when GLAND files quarterly results on BSE Start free trial →

Outcome of Board Meeting

Filed: 10 Aug 2026, 16:19 IST Exchange: NSE Category: Financial Results — Audited Results
Q1FY27 results (unaudited): Consolidated: Revenue 18.0bn +20% y-y (15.1bn) EBITDA 4.9bn +34% y-y (3.7bn) EBITDA margin 27.4% (24.4%) +300 bps y-y PAT 3.2bn +47% y-y (2.2bn) FY26 results (audited): Standalone: Revenue 45.5bn +10% y-y (41.3bn approx from prior data) EBITDA 17.7bn (derived from PBT + D&A + Finance costs - Other income, see notes) PAT 13.0bn Consolidated: Revenue 64.3bn PAT 14.3bn Dividend: Not stated Commentary: The company highlighted strong start to FY27 driven by CDMO strategy execution and robust B2B demand. Recent product launches and investments in technology and capacity expansions position the company for sustainable long-term growth.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 GLAND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add GLAND to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Gland Pharma Limited

Important. The summary above is generated automatically from Gland Pharma Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.